ABSI · Absci Corp
United States · RS rating 90 · As of 2026-11-03
| Price | 10.00 USD |
|---|---|
| 1-day change | +3.2% |
| RS rating (overall / 1M / 3M / 12M) | 90 / 30 / 89 / 96 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 52 / 75 / 40 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | +72.0% |
| Distance from 52-week high | +17.4% |
| Market cap (USD) | $617.1M |